Health & Medicine

STAT+: The FDA is targeting telehealth marketing of GLP-1 drugs. Who's prescribing them?

Ali Nemati1 day ago28 sec read8 views

The FDA is targeting telehealth companies for misleading marketing of compounded GLP-1 weight loss drugs, warning them against implying FDA approval. The crackdown also implicates affiliated medical groups that prescribe these unapproved medications, affecting at least 30% of the warned companies linked to four major nationwide medical groups. Content creators should be cautious about promoting or endorsing telehealth services related to unapproved GLP-1 drugs due to regulatory risks.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Comments

How Mexico's 'CJNG' Drug Cartel Embraced AI, Drones, and Social Media

The leader of Mexico's CJNG drug cartel is reportedly deceased, yet the organization continues to leverage advanced technologies like AI, drones, and ...The leader of Mexico's CJNG drug cartel is reportedly deceased, yet the organization continues to leverage advanced technologies like AI, drones, and social media to maintain its operations. This adaptation underscores how modern tech tools are being...

Ali Nemati

Health & Medicine15 hours ago27 sec read

STAT+: Pharmalittle: We're reading about Trump and drug prices, biotechs pushing back, and more

Trump is receiving more credit than Biden for efforts to lower drug prices in the U.S., according to a KFF poll, despite both administrations prioriti...Trump is receiving more credit than Biden for efforts to lower drug prices in the U.S., according to a KFF poll, despite both administrations prioritizing this issue; biotech companies are openly opposing Trump's plan to cap drug prices, arguing it c...

Ali Nemati

Biotech & Pharma1 day ago28 sec read

STAT+: Pharmalittle: We're reading about telehealth prescribers, a Lilly push against compounding, and more

The FDA is cracking down on telehealth companies marketing compounded versions of weight loss drugs by warning them against false claims and scrutiniz...The FDA is cracking down on telehealth companies marketing compounded versions of weight loss drugs by warning them against false claims and scrutinizing their clinical affiliations, while a key U.S. federal vaccine advisory panel has abandoned effor...

Ali Nemati

Health & Medicine1 day ago23 sec read

STAT+: Is Aldeyra Therapeutics waving red flags with consequences?

Aldeyra Therapeutics has raised concerns about short sellers ahead of an FDA approval decision, signaling potential risks for investors; this highligh...Aldeyra Therapeutics has raised concerns about short sellers ahead of an FDA approval decision, signaling potential risks for investors; this highlights the scrutiny biotech companies face from market skeptics as they await critical regulatory milest...

Ali Nemati

Health & Medicine1 day ago20 sec read

Opinion: STAT+: It's the 50th anniversary of the U.S. biotech industry. What will the next 50 years look like?

The U.S. biotech industry celebrates its 50th anniversary since Genentech's founding in 1976, marking significant advancements in health and job creat...The U.S. biotech industry celebrates its 50th anniversary since Genentech's founding in 1976, marking significant advancements in health and job creation; as content creators focus on this milestone, they should highlight the potential for future inn...

Ali Nemati

STAT+: The FDA is targeting telehealth marketing of GLP-1 drugs. Who's prescribing them?

Related Articles

How Mexico's 'CJNG' Drug Cartel Embraced AI, Drones, and Social Media

STAT+: Pharmalittle: We're reading about Trump and drug prices, biotechs pushing back, and more

STAT+: Pharmalittle: We're reading about telehealth prescribers, a Lilly push against compounding, and more

STAT+: Is Aldeyra Therapeutics waving red flags with consequences?

Opinion: STAT+: It's the 50th anniversary of the U.S. biotech industry. What will the next 50 years look like?